Surprise! Viatris Proves Its Worth With First Generic Restasis Approval
Complex Legal History And Development Challenges Surrounded Brand
In one of the most keenly-watched markets, Viatris has emerged as the winner of approval for the first US generic version of AbbVie’s Restasis 0.05% ophthalmic emulsion, years after its IP was taken down. Numerous firms and analysts had acknowledged the complexity of the reference brand.
